HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This pilot phase I trial studies the side effects and best dose of human immunodeficiency
virus (HIV)-resistant gene modified stem cells in treating HIV-positive patients who are
undergoing first-line treatment for Hodgkin or Non-Hodgkin Lymphoma. Stem cells are collected
from the patient and HIV-resistance genes are placed into the stem cells. The stem cells are
then re-infused into the patient. These genetically modified stem cells may help the body
make cells that are resistant to HIV infection.
Phase:
Phase 1
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Carmustine JM 3100 Lenograstim O(6)-benzylguanine Plerixafor Sargramostim